Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-137383

Published: 2020

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Guadalupe Oñate, MD, Ana Garrido, MD, Jordi Esteve, MD PhD, Rosa Coll, MD, Montserrat Arnan Sangerman, MD, Susana Vives, MD, Antonia Sampol, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD, Maria Paz Queipo De Llano, MD, Antoni Garcia-Guiñon, MD, Joan Bargay, MD PhD, Olga Salamero, MD, Alba Aljarilla, Salut Brunet, MD PhD, Jorge Sierra, MD, Josep Nomdedeu, MD PhD, Marta Pratcorona, MD PhD

Blood (2018) 132 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2018-99-115337

Published: 2018

Journal Articles

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Blood (2017) 130 (Supplement 1): 567.

https://doi.org/10.1182/blood.V130.Suppl_1.567.567

Published: 2017

Journal Articles

Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)

Blood (2017) 130 (Supplement 1): 1273.

https://doi.org/10.1182/blood.V130.Suppl_1.1273.1273

Published: 2017

Journal Articles

Renal Response in Relapsed Refractory Multiple Myeloma Patients with Severe Renal Impairment at treatment Initiation: Intermediate Data of a Large, Observational, Prospective Study

Blood (2017) 130 (Supplement 1): 1878.

https://doi.org/10.1182/blood.V130.Suppl_1.1878.1878

Published: 2017

Journal Articles

Renal Response in Patients with Relapsed Refractory Multiple Myeloma: Interim Data of a Large, Observational, Prospective Study

Blood (2016) 128 (22): 2114.

https://doi.org/10.1182/blood.V128.22.2114.2114

Published: 2016

Journal Articles

Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Blood (2015) 126 (23): 2514.

https://doi.org/10.1182/blood.V126.23.2514.2514

Published: 2015

Journal Articles

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Blood (2012) 120 (21): 1452.

https://doi.org/10.1182/blood.V120.21.1452.1452

Published: 2012

Journal Articles

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Blood (2010) 116 (21): 1712.

https://doi.org/10.1182/blood.V116.21.1712.1712

Published: 2010

Journal Articles

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Blood (2010) 116 (21): 1066.

https://doi.org/10.1182/blood.V116.21.1066.1066

Published: 2010

Journal Articles

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Blood (2009) 114 (22): 4711.

https://doi.org/10.1182/blood.V114.22.4711.4711

Published: 2009

NARROW

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)

Renal Response in Relapsed Refractory Multiple Myeloma Patients with Severe Renal Impairment at treatment Initiation: Intermediate Data of a Large, Observational, Prospective Study

Renal Response in Patients with Relapsed Refractory Multiple Myeloma: Interim Data of a Large, Observational, Prospective Study

Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only